Development and evaluation of ActSeq: A targeted next-generation sequencing panel for clinical oncology use

被引:4
|
作者
Shi, Zonggao [1 ,5 ]
Lopez, Jacqueline [2 ]
Kalliney, William [1 ,3 ,5 ]
Sutton, Bobbie [3 ]
Simpson, Joyce [3 ]
Maggert, Kevin [3 ]
Liu, Sheng [4 ,6 ]
Wan, Jun [4 ,6 ]
Stack, M. Sharon [1 ,5 ]
机构
[1] Univ Notre Dame, Harper Canc Res Inst, Notre Dame, IN USA
[2] Univ Notre Dame, Genom & Bioinformat Core Facil, Notre Dame, IN USA
[3] South Bend Med Fdn, South Bend, IN USA
[4] Indiana Univ Sch Med, Collaborat Core Canc Bioinformat, Indianapolis, IN USA
[5] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN USA
[6] Indiana Univ Sch Med, Dept Med & Mol Genet, United 0States Amer, Indianapolis, IN USA
来源
PLOS ONE | 2022年 / 17卷 / 04期
关键词
CANCER;
D O I
10.1371/journal.pone.0266914
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
PurposeThe demand for high-throughput genetic profiling of somatic mutations in cancer tissues is growing. We sought to establish a targeted next generation sequencing (NGS) panel test for clinical oncology practice. MethodsCustomized probes were designed to capture exonic regions of 141 genes selected for the panel, which was aimed for the detection of clinically actionable genetic variations in cancer, including KRAS, NRAS, BRAF, ALK, ROS1, KIT and EGFR. The size of entire targeted regions is 0.8 Mb. Library preparation used NEBNext Ultra II FS kit coupled with target enrichment. Paired-end sequencing was run on Illumina NextSeq 500 at a read length of 150 nt. A bioinformatics workflow focusing on single nucleotide variant and short insertions and deletions (SNV/indel) discovery was established using open source, in-house and commercial software tools. Standard reference DNA samples were used in testing the sensitivity and precision and limit of detection in variant calling. ResultsThe general performance of the panel was observed in pilot runs. Average total reads per sample ranged from 30 million to 48 million, 73% ~82% unique reads. All runs had more than 99% average mapping rate. Mean target coverage ranged from 727x to 879x. Depth of coverage at 50x or more reached 87% of targeted region and 60% of targeted region received 500x or more coverage depth. Using OncoSpan HD827 DNA, which bears 144 variants (SNV/indel) from 80 genes that are within the targeted region on the panel, our somatic variant calling pipeline reached 97% sensitivity and 100% precision respectively, with near 48 million reads. High concordance with orthogonal approaches in variant detection was further verified with 7 cancer cell lines and 45 clinical specimens. ConclusionWe developed a NGS panel with a focus on clinically actionable gene mutations and validated the performance in library construction, sequencing and variant calling. High concordance with reference materials and orthogonal mutation detection was observed.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] A Targeted Next-Generation Sequencing Panel to Genotype Gliomas
    Guarnaccia, Maria
    Guarnaccia, Laura
    La Cognata, Valentina
    Navone, Stefania Elena
    Campanella, Rolando
    Ampollini, Antonella
    Locatelli, Marco
    Miozzo, Monica
    Marfia, Giovanni
    Cavallaro, Sebastiano
    LIFE-BASEL, 2022, 12 (07):
  • [2] Clinical utility of next-generation sequencing in precision oncology
    Hux, Anna
    Lewis, Amanda
    Sachwitz, Drew
    Gregory, Tanya
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2019, 32 (01): : 35 - 39
  • [3] A Canadian guideline on the use of next-generation sequencing in oncology
    Yip, S.
    Christofides, A.
    Banerji, S.
    Downes, M. R.
    Izevbaye, I.
    Lo, B.
    MacMillan, A.
    McCuaig, J.
    Stockley, T.
    Yousef, G. M.
    Spatz, A.
    CURRENT ONCOLOGY, 2019, 26 (02) : E241 - E254
  • [4] Evaluation of Targeted Next-Generation Sequencing for Detection of Bovine Pathogens in Clinical Samples
    Anis, Eman
    Hawkins, Ian K.
    Ilha, Marcia R. S.
    Woldemeskel, Moges W.
    Saliki, Jeremiah T.
    Wilkes, Rebecca P.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2018, 56 (07)
  • [5] Validation and clinical application of a targeted next-generation sequencing gene panel for solid and hematologic malignancies
    Prieto-Potin, Ivan
    Carvajal, Nerea
    Plaza-Sanchez, Jenifer
    Manso, Rebeca
    Laura Auz-Alexandre, Carmen
    Chamizo, Cristina
    Zazo, Sandra
    Lopez-Sanchez, Almudena
    Maria Rodriguez-Pinilla, Socorro
    Camacho, Laura
    Longaron, Raquel
    Bellosillo, Beatriz
    Somoza, Rosa
    Hernandez-Losa, Javier
    Manuel Fernandez-Soria, Victor
    Ramos-Ruiz, Ricardo
    Cristobal, Ion
    Garcia-Foncillas, Jesus
    Rojo, Federico
    PEERJ, 2020, 8
  • [6] Validation of a targeted next-generation sequencing panel for pancreatic ductal adenocarcinomas
    Racu, Marie-Lucie
    Schiavo, Andrea Alex
    Van Campenhout, Claude
    De Neve, Nancy
    Masuy, Thomas
    Maris, Calliope
    Decaestecker, Christine
    Remmelink, Myriam
    Salmon, Isabelle
    D'Haene, Nicky
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2024, 139
  • [7] Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories
    Mendez, Pedro
    Dang, Jennifer
    Kim, James Wansoo
    Lees, Sharon
    Yoon, Jun-Hee
    Kim, Thomas
    Sailey, Charles J.
    Jablons, David M.
    Kim, Il-Jin
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 49 (01) : 235 - 242
  • [8] Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma
    Marinoff, Amanda E.
    Spurr, Liam F.
    Fong, Christina
    Li, Yvonne Y.
    Forrest, Suzanne J.
    Ward, Abigail
    Doan, Duong
    Corson, Laura
    Mauguen, Audrey
    Pinto, Navin
    Maese, Luke
    Colace, Susan
    Macy, Margaret E.
    Kim, Aerang
    Sabnis, Amit J.
    Applebaum, Mark A.
    Laetsch, Theodore W.
    Glade-Bender, Julia
    Weiser, Daniel A.
    Anderson, Megan
    Crompton, Brian D.
    Meyers, Paul
    Zehir, Ahmet
    Macconaill, Laura
    Lindeman, Neal
    Nowak, Jonathan A.
    Ladanyi, Marc
    Church, Alanna J.
    Cherniack, Andrew D.
    Shukla, Neerav
    Janeway, Katherine A.
    JCO PRECISION ONCOLOGY, 2023, 7
  • [9] Oncologist use and perception of large panel next-generation tumor sequencing
    Schram, A. M.
    Reales, D.
    Galle, J.
    Cambria, R.
    Durany, R.
    Feldman, D.
    Sherman, E.
    Rosenberg, J.
    D'Andrea, G.
    Baxi, S.
    Janjigian, Y.
    Tap, W.
    Dickler, M.
    Baselga, J.
    Taylor, B. S.
    Chakravarty, D.
    Gao, J.
    Schultz, N.
    Solit, D. B.
    Berger, M. F.
    Hyman, D. M.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2298 - 2304
  • [10] Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms
    Au, Chun Hang
    Wa, Anna
    Ho, Dona N.
    Chan, Tsun Leung
    Ma, Edmond S. K.
    DIAGNOSTIC PATHOLOGY, 2016, 11